EPCAM and breast carcinoma: The noninvasive detection of CTCs in peripheral blood of patients has become a useful clinical tool in other cancers, such as breast cancer [12], but the conventional CTC-capture marker EpCAM is only expressed in 30-40% of RCC and thus is not an ideal capture antigen for the detection of CTCs in RCC patients [13].